Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dive deep into mesothelioma tumors to unlock new treatment clues

NCT ID NCT06581549

Knowledge-focused Sponsor: Istituto Oncologico Veneto IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is looking at tumor samples from 220 people with pleural or peritoneal mesothelioma, a rare cancer linked to asbestos. Researchers will analyze the genes and immune cells in these tumors to find patterns that could predict which treatments work best. The goal is to improve personalized medicine for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could identify new drug targets and better ways to match treatments to individual mesothelioma patients.
What could go wrong
This is an observational study analyzing existing samples, not testing a new treatment directly. Results may not lead to immediate therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

220 PPM patients will be enrolled in 7 Centers, 150 retrospectively and 70 prospectively.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with Mesothelioma of the Pleura and Peritoneum * Age greater than 18 years of age * Patients undergoing surgery will require both biopsy and surgical sampling material * Pathologist's confirmation of the presence of tumor sections in the excised specimens * Patients in follow-up from active cancer treatment for at least 6 months Exclusion Criteria: * Inadequacy of biological material for analysis under study * Patients not amenable to active oncologic treatment * Patients lost to follow-up before 6 months after the end of active oncologic treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mesothelioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pleural mesothelioma mesothelioma Mesothelioma, Malignant peritoneal mesothelioma pleural mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mesothelioma Mesothelioma; lung Mesotheliomas pleural

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    10 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Asst Grande Ospedale Metropolitano Niguarda-Milano

    RECRUITING

    Milan, Italy

  • Asst Papa Giovanni Xxiii Bergamo

    RECRUITING

    Bergamo, Italy

  • Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo

    RECRUITING

    Alessandria, 15121, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona

    RECRUITING

    Verona, Italy

  • Azienda Ospedaliera-Universitaria di Parma

    RECRUITING

    Parma, 43126, Italy

  • Centro di Riferimento Oncologico (CRO) IRCCS

    RECRUITING

    Aviano, Pordenone, 33081, Italy

  • Fondazione Ircss Istituto Nazionale Dei Tumori Di Milano

    RECRUITING

    Milan, Italy

  • Ircss Ospedale Policlinico San Martino

    RECRUITING

    Genova, Italy

  • Istituto Clinico Humanitas

    RECRUITING

    Rozzano, Milano, 20089, Italy

  • Istituto Oncologico Veneto

    RECRUITING

    Padova, 35128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.